Shanghai Baolong Biotechnology

Shanghai Baolong Biotechnology is a Chinese biopharmaceutical company focused on the development and commercialization of high-end biologics, particularly biosimilars. Established as a strategic diversification of the publicly traded Shanghai Baolong Automotive Corporation, the company leverages its parent's resources to advance a pipeline of monoclonal antibodies targeting significant therapeutic areas such as oncology, immunology, and bone health. Its lead candidate, BL-M11, is a biosimilar of denosumab targeting RANKL for the treatment of osteoporosis and giant cell tumors of bone, currently in late-stage clinical development. The company's portfolio also includes biosimilars for major biologics like bevacizumab, trastuzumab, and adalimumab. Shanghai Baolong Biotechnology operates R&D and manufacturing facilities in Shanghai, aiming to provide affordable, high-quality biological treatments to the Chinese market.